Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Spero Therapeutics (SPRO) EBIT (2016 - 2025)

Historic EBIT for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to -$7.9 million.

  • Spero Therapeutics' EBIT rose 5742.48% to -$7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$46.8 million, marking a year-over-year decrease of 176073.08%. This contributed to the annual value of -$73.4 million for FY2024, which is 38877.74% down from last year.
  • According to the latest figures from Q3 2025, Spero Therapeutics' EBIT is -$7.9 million, which was up 5742.48% from -$2.4 million recorded in Q2 2025.
  • Over the past 5 years, Spero Therapeutics' EBIT peaked at $54.5 million during Q4 2023, and registered a low of -$30.2 million during Q1 2022.
  • For the 5-year period, Spero Therapeutics' EBIT averaged around -$10.7 million, with its median value being -$14.7 million (2025).
  • As far as peak fluctuations go, Spero Therapeutics' EBIT skyrocketed by 19734.2% in 2022, and later crashed by 86137.54% in 2024.
  • Quarter analysis of 5 years shows Spero Therapeutics' EBIT stood at -$27.5 million in 2021, then skyrocketed by 197.34% to $26.8 million in 2022, then soared by 103.41% to $54.5 million in 2023, then tumbled by 139.9% to -$21.7 million in 2024, then skyrocketed by 63.56% to -$7.9 million in 2025.
  • Its last three reported values are -$7.9 million in Q3 2025, -$2.4 million for Q2 2025, and -$14.7 million during Q1 2025.